Sector · healthcare-life-sciences

Diagnostics and pathology consulting

From laboratory to clinical pathway – strategy for diagnostics businesses entering new markets.

Primary research in every engagement 100+ mandates delivered Go/Defer/Kill recommendation guaranteed
Talk to an expert Free diagnostic →
Our POV · 2026

Diagnostics and pathology consulting

The diagnostics sector is experiencing rapid transformation – with molecular diagnostics, point-of-care testing, AI-powered digital pathology, and liquid biopsy all creating new market entry opportunities alongside the continued growth of traditional laboratory diagnostics. Diagnostics companies, pathology laboratory operators, diagnostic equipment manufacturers, and clinical laboratory information system providers are all evaluating new market entry opportunities across Southeast Asia, South Asia, and the Gulf. GreyRadius helps diagnostics businesses validate clinical demand, navigate regulatory requirements, and raise capital.

Why now? Healthcare infrastructure investment is driving diagnostics market growth – new hospital construction, national health insurance expansion, and disease burden management programmes are all creating funded diagnostics demand. Early disease detection programmes in the Gulf and Southeast Asia are creating specific demand for advanced molecular and cancer diagnostics.

Market Intelligence

What the data says.

Diagnostics market in Southeast Asia is growing at 9% annually – driven by hospital expansion, NHI inclusion of diagnostic tests, and rising patient awareness of preventive diagnostics.

Point-of-care diagnostics is the fastest-growing segment – rapid tests for infectious diseases, chronic disease management, and STIs are achieving high adoption in primary care and community health settings.

AI digital pathology is transforming histopathology – AI-assisted tissue analysis is reducing pathologist workload and improving diagnostic accuracy, creating significant commercial opportunities in markets with pathologist shortages.

Genetic and genomic diagnostics are expanding rapidly in affluent markets – consumer genomics, pharmacogenomics, and hereditary cancer screening are all growing in the Gulf, Singapore, and urban India.

Market Reality

What makes this market hard.

  • Regulatory approval for diagnostic devices is complex – IVD registration requirements, clinical performance data requirements, and CE/FDA marking needs vary across markets and require significant compliance investment.
  • Reimbursement for advanced diagnostics is limited in many markets – molecular diagnostics and genetic testing are rarely on government insurance formularies, limiting addressable market to out-of-pocket payers.
  • Cold chain requirements for molecular diagnostic reagents create distribution complexity – temperature-sensitive reagents require cold chain infrastructure from import to point of use.
  • Price competition from established Chinese and domestic diagnostic equipment manufacturers is intensifying in cost-sensitive segments – competing on price alone is unsustainable for international entrants.
Our Work

What we solve for clients.

If you recognise your situation below, we can help.

Diagnostics market demand and channel assessment

You need to understand test volume potential, ordering physician behaviour, and the competitive diagnostic landscape in your target market.

Regulatory registration pathway

You need to understand IVD registration requirements, performance data requirements, and approval timelines in your target market.

Laboratory and hospital partner identification

You need to identify reference laboratories, hospital laboratory networks, and diagnostic chains as potential distribution partners or customers.

GTM for diagnostic equipment or reagents

You have a diagnostic analyser, reagent, or IVD kit and need a go-to-market strategy covering laboratory and hospital acquisition.

Raising capital for a diagnostics venture

You are raising investment and need a pitch book grounded in test volume data and market sizing.

Competitive intelligence

You need to understand how competing diagnostic companies are positioned and winning laboratory contracts in your target market.

Our Services

How we engage.

Every engagement is grounded in primary research and delivers a measurable outcome.

Opportunity Assessment

Validate clinical demand and market opportunity for diagnostic products in a new market. Covers physician and laboratory interviews, regulatory mapping, competitive analysis, and a Go/Defer/Kill recommendation.

Learn more →
Feasibility & TEV

Full financial and operational feasibility for diagnostics investments. Covers test volume modelling, distribution cost structure, regulatory compliance cost, and bankable financial projections.

Learn more →
Market Entry Execution

End-to-end market entry for diagnostics companies. Regulatory registration pathway, laboratory and hospital partner identification, and first-laboratory or first-hospital acquisition.

Learn more →
GTM Execution-as-a-Service

Embedded GTM team for diagnostic equipment and IVD companies. Laboratory and hospital outreach, reference laboratory pipeline, and first-revenue milestone tracking.

Learn more →
Pitchbook & Fundraising

Investor-ready pitch books for diagnostics ventures. Test-volume-validated market sizing, regulatory pathway clarity, and investor identification.

Learn more →
AI Consulting

AI use-case prioritisation in diagnostics – from automated image analysis and result interpretation to laboratory workflow optimisation and predictive test ordering.

Learn more →

Why GreyRadius.

Primary research-led

80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.

Expert-led, AI-enabled delivery

Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.

Outcomes, not reports

We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.

200+

Projects delivered

100+

SaaS & tech clients

80%

Primary research-led

4

Countries / offices

Not sure where to start?

Our free diagnostic tells you which service fits your situation

Answer 3 questions about your business stage and market entry goal. Takes 90 seconds. We will tell you which GreyRadius service applies and what a first engagement would look like.

Run the free diagnostic → Speak to an expert directly

Free. No commitment. No sales pitch in the first call.

100+

mandates delivered since 2017

30+

primary expert interviews per engagement

4

geographies – India, Gulf, Southeast Asia, Africa

8+

years of emerging market engagements

What clients say

GreyRadius gave us the market intelligence we needed to enter GCC with confidence – validated KOL contacts, distributor shortlists, and a regulatory timeline that was 30% faster than our original estimate.

Head of International Business

Ophthalmology pharma company · GCC market entry and regulatory mapping

The buyer research was the turning point. We'd spent 12 months building pipeline in the wrong markets. GreyRadius told us where the real demand was, validated by actual decision-makers – not polite interest.

CEO

UAE-based EdTech platform · GCC market entry strategy

Case Studies

Mandates we've run.

Healthcare · Market Entry

Gulf market entry for a South Asian pharma company

Regulatory mappedDistributor shortlistFirst listings
View all case studies →

Healthcare · GTM Execution

GTM for a digital-health platform in Southeast Asia

Clinic partnershipsB2B pipelineFirst ARR
View all case studies →

Healthcare · Assessment

Opportunity assessment for a medical-device launch in India

Clinical interviewsRegulatory reviewRevenue model
View all case studies →
FAQ

Common questions.

Does GreyRadius work with IVD manufacturers or also with laboratory operators and digital diagnostics companies? +

All three. We work with IVD manufacturers on market entry, laboratory operators on market entry and GTM, and digital diagnostics companies on market entry and fundraising.

What diagnostics markets does GreyRadius cover? +

Southeast Asia, South Asia, and the Gulf – markets with significant diagnostic demand growth.

How long does a diagnostics market entry engagement take? +

Typically 8–10 weeks given the complexity of regulatory mapping and clinical demand research.

Can GreyRadius identify reference laboratory partners for diagnostics companies? +

Yes. Laboratory partner identification and initial commercial conversations are part of our market entry execution service.

Stay informed

Market intelligence for healthcare-life-sciences leaders.

GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.

Not sure which engagement fits?  Take our free 2-minute diagnostic →

When you get in touch

What happens after you contact us

1

Discovery call

30 minutes. We learn your situation. You learn how we work.

Within 48 hours

2

Engagement scoped

Scope, research plan, and outcomes agreed before work begins.

Week 1

3

Primary research

30+ expert interviews. Buyers, regulators, distributors, competitors.

Weeks 2–5

4

Recommendation delivered

Go/Defer/Kill with the primary evidence your board needs to act.

Week 6–8

Ready to enter this market?

Choose the option that matches where you are right now. No commitment required at any stage.

Starting out

Run our free diagnostic

Answer 3 questions about your situation. Get a personalised service recommendation in 90 seconds.

Start the diagnostic →

Evaluating options

See how we structure an engagement

Download our one-page overview – scope, timeline, deliverable format, and what primary research produces.

Request the overview →

Ready to start

Book a 30-minute call

Speak with a GreyRadius partner. No pitch – we will tell you what primary research in your sector and market would actually reveal.

Book the call →

Typical first response within 4 business hours.

Book a call

Speak with a GreyRadius expert.

Free Expert Assessment